Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04327180
Other study ID # 2020_20
Secondary ID 2020-A00763-36
Status Completed
Phase
First received
Last updated
Start date March 30, 2020
Est. completion date January 30, 2021

Study information

Verified date December 2023
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Coronavirus 2019 (COVID-19) is a respiratory tropism virus transmitted through droplets emitted into the environment of infected persons. The symptoms can be extremely varied and the course can range from spontaneous healing without sequelae to death. Currently, the diagnosis of certainty for resuscitation patients (by definition "severe") is based on searching for a fragment of virus genetic material within the epithelial cells of the respiratory tree, up and/or down, by PCR. It is to be expected that the epidemic peak will make it difficult (if not impossible) to respect the stereotypical path that is currently in place, due to the lack of space in the specific unit. This will require optimization of care pathways and use of the specific sectors. It is therefore necessary to define the simple criteria, available from the moment patients are admitted, to predict the result of the COVID-19 PCR.


Recruitment information / eligibility

Status Completed
Enrollment 368
Est. completion date January 30, 2021
Est. primary completion date January 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patient admitted in ICU Lille Hospital and hospitalized in the unit "Emergent Biological Risk" (REB) before a suspicion of infection with COVID-19 - Clinical infectious syndrome: fever (>38°C) or hypothermia ( 36°C), chill, fever at home - a severe respiratory table defined by: - Oxygen demand > 3 L/min in the presence of significant comorbidity (pregnancy, chronic respiratory disease, chronic heart disease, hemopathy, cirrhosis) or > 6 L/min in the absence of comorbidity - or a respiratory rate > 30 cycles per minute - the need for mechanical, invasive or non-invasive ventilation - the need for humidified high-flow oxygen therapy Exclusion Criteria: - Patient already included in study for first stay - Cirrhosis CHILD C - Major surgery in the last 7 days Minor patient - Patient under guardianship or curatorship - Refusal to participate - No social security coverage.

Study Design


Locations

Country Name City State
France Hôpital Roger Salengro, ICU, CHU Lille Lille

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU within 24 hours of admission to ICU
Secondary Coinfections Assessment of viral, bacterial, fungal and parasitic rate in confirmed and unconfirmed patients for COVID-19 during ICU stay, up to 28 days
Secondary Respiratory dysfunction requiring mechanical ventilation it will be reported the evolution of respiratory dysfunction in patients infected with COVID-19 admitted to ICU during their stay and requiring mechanical ventilation (during, Pao2/FIO2 ratio,,features of artificial ventilation features of extra-bodied respiratory assistance) during ICU stay, up to 28 days
Secondary Sequential Organ Failure Assessment (SOFA) Score the SOFA assessment is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). during ICU stay, up to 28 days
Secondary SAPS II score APS II was designed to measure the severity of disease for patients admitted to Intensive care units 24 hours after admission to the ICU, the measurement has been completed and resulted in an integer point score between 0 and 163 and a predicted mortality between 0% and 100%. at admission
Secondary Disseminated Intravascular Coagulation (DIC) score The DIC Score was developed by the The International Society of Thrombosis and Haemostasis (ISTH.) The DIC score calculator accounts of the following four parameters.Each of the four parameters evaluated above have values that are weighted with a number of points varying from 0 to 3. By summing the points given to the choices, a final result between 0 and 8 is obtained during ICU stay, up to 28 days
Secondary Number of days on vasopressive amines during ICU stay, up to 28 days
Secondary Occurrence of an event of venous or arterial thromboembolic disease during ICU stay, up to 28 days
Secondary Number of days with extra renal treatment (ERA) during ICU stay, up to 28 days
Secondary Number of patients alive after ICU stay less than 28 days will be tracked At 28 day
Secondary Short Form 36 measuring the long-term impact of confirmed COVID-19 infection. assessment of quality of life according to 8 areas: physical activity (and related limitations), body pain, perception of one's own health, mental health (and related limitations), social life and vitality. at 9 months +/- 3 months after ICU stay
Secondary Hospital anxiety and depression scale (HADS) The scale allows to detect anxiety and depression using 14 items rated from 0-3.
Measuring the long-term impact of confirmed COVID-19 infection
at 9 months +/- 3 months after ICU stay
Secondary Impact of Event Scale - revised (IES-R) 22-item self-report measure that assesses subjective distress caused by traumatic events Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88) Measuring the long-term impact of confirmed COVID-19 infection at 9 months +/- 3 months after ICU stay
Secondary Post-traumatic stress disorder Checklist version DSM-5 (PSL-5) Question the stressful experience or event, followed by 20 multiple-choice questions.
Measuring the long-term impact of confirmed COVID-19 infection
at 9 months +/- 3 months after ICU stay
Secondary Modified Medical Research Council (MMRC) Dyspnea Scale The mMRC Dyspnea Scale stratifies severity of dyspnea in respiratory diseases Measuring the long-term impact of confirmed COVID-19 infection at 9 months +/- 3 months after ICU stay
Secondary Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters until day 28 after admission of ICU
Secondary Viral clearance Evolution of viral clearance in nasal and depp PCR during ICU through study completion, an average of 28 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01416506 - Community-Acquired Pneumonia (CAP) Surveillance N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4